Shopping Cart
- Remove All
- Your shopping cart is currently empty
Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker. Arotinolol also shows potency for inhibiting the binding of the radioligand [125I-ICYP] to [5HT1B-serotonergic] receptor sites. It is an antihypertensive agent.
Description | Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker. Arotinolol also shows potency for inhibiting the binding of the radioligand [125I-ICYP] to [5HT1B-serotonergic] receptor sites. It is an antihypertensive agent. |
In vitro | Arotinolol shows its selectivity of β-adrenergic receptors, the result of Arotinolol for β1 and β2 adrenoceptors in 125I-ICYP binding to rat cerebral cortical membranes with pKi value of 9.74 and 9.26 respectively. Arotinolol shows its potency for inhibiting the binding of the same radioligand to the 5HT1B-serotonergic receptor site, Arotinolol displaces 125I-ICYP binding to 5HT1B-receptors (pKis: 7.97 and 8.16 for β1 and β2 adrenergic receptors) [2]. |
In vivo | Arotinolol (oral gavage; 200 mg/kg; 8 weeks) significantly decreases central arterial pressure (CAP) and pulse wave velocity (PWV), reduces aortic collagen depositions, and improves arterial stiffness in SHR mouse [1]. |
Molecular Weight | 371.54 |
Formula | C15H21N3O2S3 |
Cas No. | 68377-92-4 |
Relative Density. | 1.35 g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 250 mg/mL (672.88 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.